J.Jpn. Surg. Soc.. 90(9): 1455-1458, 1989

---

Report on the annual meeting

CLINICAL EFFICACY OF LAK CELL ADOPTIVE IMMUNOTHERAPY IN ADVANCED CANCER PATIENTS

Clinical efficacy of lymphokine-activated killer (LAK) cell adoptive immunotherapy (AIT) in combination with plasma exchange was investigated as protocol 1 in 24 patients with advanced cancer. For the development of protocol 1, AIT in combination with plasma exchange, OK-432, interleukin-2 (IL-2) and cyclophosphamide was performed as protocol 2, in which LAK cells, OK-432 and IL-2 were administered through the catheter located in the hepatic or bronchial artery. The clinical efficacy of protocol 1 was found in patients with pleural effusion and metastasis to the lung or liver and resulted in 4 partial responses (20％) and 1 minor response of 20 evaluable cases. On the other hand, that of protocol 2 did 1 partial reponse (20％) in 5 cases. In vitro cytotoxic activity against either Daudi or K 562 tumor cells of peripheral blood lymphocytes from patientic given intraaorta administrations of OK-432 and IL-2 was tended to increase to be higher than that from nontreated patients. Postoperative immunodepression in esophageal cancer was blocked by AIT, suggesting the usefulness of AIT as a postoperative adjuvant immunotherapy. Thus, target organ of AIT should be limited for better therapeutic effect and the superiority of local AIT in combination with biological response modifiers may be indicated.

---

---

To read the PDF file you will need Adobe Reader installed on your computer.